Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
20%
Ph early_phase_1
2
20%
Ph phase_2
3
30%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
2(28.6%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(3)
Terminated(2)

Detailed Status

Recruiting5
Completed3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (28.6%)
Phase 12 (28.6%)
Phase 23 (42.9%)

Trials by Status

withdrawn220%
completed330%
recruiting550%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_1

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
completed

MRI for Screening and Monitoring Scleroderma ILD

NCT05204355
recruiting

Hyperpolarized 129Xe MRI Lung Health Cohort

NCT05766384
completed

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

NCT05339386
completedphase_1

Hyperpolarized 129Xe MRI of Survivors of COVID-19

NCT04659707
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04624490Phase 1

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Recruiting
NCT05204355

MRI for Screening and Monitoring Scleroderma ILD

Completed
NCT05766384

Hyperpolarized 129Xe MRI Lung Health Cohort

Recruiting
NCT05339386

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

Completed
NCT04659707Phase 1

Hyperpolarized 129Xe MRI of Survivors of COVID-19

Completed
NCT06038630Phase 2

129Xe MRI Cardiopulmonary

Recruiting
NCT06339593Early Phase 1

Regional Monitoring of CF Lung Disease

Recruiting
NCT06853145Early Phase 1

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

Recruiting
NCT06122922Phase 2

Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Withdrawn
NCT04677426Phase 2

129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10